Searchable abstracts of presentations at key conferences in endocrinology

ea0081ep713 | Pituitary and Neuroendocrinology | ECE2022

Bronchial carcinoma as debut in MEN-1 Syndrome

Justel Enriquez Alicia , Torcal Carolina Knott , Blanco Sara Jime nez , Moreno Victor Navas , Marazuela Monica

Background: Neuroendocrine tumors present in the MEN-1 syndrome are usually located in pancreatic islets and more than 10% appear de novo, affecting any age group. The debut of a carcinoid tumor is rare, with a prevalence of 2% of bronchial carcinoid tumors. Materials and methods: We present the case of a 49-year-old woman referred from the Oncology clinic for the assessment of thyroid incidentalomas found in a follow-up CT scan of multifocal bronchial c...

ea0041ep571 | Diabetes therapy | ECE2016

Analysis and metabolic evaluation in a standard clinical setting of a group of patients 7 years after a clinical trial with sensor-augmented pump (SAP)

Dominguez-Lopez Marta , Colomo Rdriguez Natalia , Soledad Ruiz de Adana Navas M

Background and objective: Several trials showed that sensor-augmented pump (SAP) therapy is safe and effective to reduce hypoglycemic events and improve glicemic control with high treatment satisfaction. Nevertheless patient adherence and sensor use in trials usually decrease with time. Our objective was to evaluate metabolic control and adherence and sensor use after initiation of SAP in a clinical trial.Methods: In 2008 we recruited 25 patients in trea...

ea0016p551 | Obesity | ECE2008

Prevalence of non alcoholic steatohepatitis in diabetic patients with morbid obesity

Segovia Raquel , Camara Rosa , Del Olmo Maribel , Ponce Jose , Navas Soledad , Argente Maria , Pinon Francisco

Non alcoholic steatohepatitis (EHNA) is diagnosed by hepatic biopsy. Its etiology is uncertain but obesity is present in 69–100% of all cases and type 2 diabetes mellitus (DM) in about 34–75%.Objectives: To study the prevalence of EHNA in morbidly obese patients and determine if there is a difference between the prevalence in patients with and without carbohydrate metabolism disorders.Patients and methods: Prospective stu...

ea0003p84 | Diabetes & Metabolism | BES2002

The effect of growth hormone replacement (GHR) on lipoprotein composition in growth hormone deficient (GHD) hypopituitary adults

Kearney T , Proudler A , Navas|#de Gallegos C , Robinson S , Venkatesan S , Johnston D

Background. Abnormal lipoprotein composition associated with growth hormone deficiency (GHD) may contribute to increased mortality observed in conventionally replaced hypopituitarism. Aim. To examine the effects of forty weeks of growth hormone replacement (GHR) on lipoprotein composition and LDL size in sixteen GHD hypopituitary subjects. In eight patients, VLDL and LDL composition were additionally assessed after eight weeks. Methods. VLDL and LDL were separated by different...

ea0032p486 | Diabetes | ECE2013

Evaluation of adolescents with type 1 diabetes after transition from paediatric to adult care

Dominguez-Lopez Marta , Gonzalez-Molero Inmaculada , Lopez-Siguero Juan Pedro , Navas MSoledad Ruiz de Adana , Escofet Federico Soriguer

Objective: Our objective in this study was to identify the type of clinical care received by young type 1 diabetic patients who have made the transition from paediatric to adult care, and to assess the metabolic status of the patients. The research aimed to develop a sustainable and coordinated approach to facilitating the transition between diabetes services for adolescents and reveal from the perspective of the adolescents living with type 1 diabetes their experiences surrou...

ea0026p663 | Diabetes therapy | ECE2011

Evaluation of adolescents type 1 diabetic patients after transition from paediatric to adult care

Dominguez-Lopez M , Gonzalez-Molero I , RuizdeAdana-Navas S , delPino A , Lopez J P , Fernandez J D , Olveira G , Soriguer F

Objective: Our objective in this study was to identify the type of clinical care received by young type 1 diabetic patients who have made the transition from paediatric to adult care, and to assess the metabolic status of the patients. The research aimed to develop a sustainable and coordinated approach to facilitating the transition between diabetes services for adolescents and reveal from the perspective of the adolescents living with type 1 diabetes their experiences surrou...

ea0003p83 | Diabetes & Metabolism | BES2002

Effects of growth hormone replacement (GHR) on VLDL and LDL APOB100 kinetics in growth hormone deficient (GHD) subjects

Kearney T , Navas|#de Gallegos C , Miras A , Parker K , Anayaouku V , Gray R , Venkatesan S , Johnston D

Background. Hypopituitarism is associated with increased VLDL and LDL apoB concentrations, which may be attributable to GHD. Studies examining the effects of GHR on VLDL apoB kinetics have been conflicting, possibly due to differences in the duration of GHR. As yet, the effects of GHR on LDL apoB kinetics are unknown. Aim. To examine the effect of GHR on VLDL and LDL apoB kinetics, and to explore the hypothesis that these effects are dependent on the duration of therapy. Metho...

ea0056gp95 | Diabetes Therapy | ECE2018

Randomized control study to compare security and efficacy of the new long acting analogues degludec and glargina U300 in people with type 1 Diabetes. Preliminary results of the Ineox study

Dominguez-Lopez Marta Elena , Vallejo Rosario , Morillas Virginia , Colomo Natalia , Guerrero Mercedes , Rojo Gema , de Adana Navas Marisol Ruiz

Background: There aren’t published randomized studies comparing the clinical impact of degludec and Glragina U300 in the treatment of type 1 diabetes patients. (T1DP)Objective: To compare efficacy and safety of the new long acting analogues Glargine U 300 and Degludec in 300 Type1 diabetes patients treated with basal/bolus treatment.(BBT)Material and methods: Randomized control study 1.1 in 300 T1DP treated with BBT with glarg...

ea0041ep557 | Diabetes therapy | ECE2016

Randomized clinical trial to compare the effects of glargine multidosis versus CSII therapy on metabolic and oxidative stress parameters in people with type 1 diabetes

de Adana Navas M Soledad Ruiz , Dominguez-Lopez Marta , Rubio Eleazara , Rodriguez Natalia Colomo , Cardona Isabel , Tapia M Jose , Morillas Virgina , Gonzlez Inmaculada , Rojo Gemma

Aims: There are few data comparing oxidative stress markers in CSII versus MDI/G We compared after randomization CSII (Continuous subcutaneous insulin infusion) vs MDI/G therapy (multiple doses of insulin with glargine) in DM1 people previously optimized at MDI/G being the primary objective assessment of metabolic control and oxidative stress.Assess oxidative stress and metabolic control in patients with type 1 diabetes (T1D) after randomization in CSII ...

ea0029p27 | Adrenal cortex | ICEECE2012

Importance of the genetic study in fertile women with nonclassical congenital adrenal hyperplasia

Rubio-Almanza M. , Navas-de Solis S. , Tenes-Rodrigo S. , Querol Ripoll R. , Perez-Lazaro A. , del Olmo-Garcia M. , Merino-Torres J.

The Nonclassical Congenital Adrenal Hyperplasia (NCCAH) is an autosomal recessive disorder. The importance of the diagnosis in fertile women relies in its therapeutic implications, genetic counseling and antenatal care during pregnancy. Diagnosis is established by the presence of basal 17-OH-progesterone (17-OHP) levels ≧6 ng/ml or stimulated after ACTH test ≧15 ng/ml. Basal values between 2-6 ng/ml or stimulated between 10–15 ng/ml would require further con...